RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer

A previous randomized phase II trial suggested that sorafenib might enhance the efficacy of capecitabine in patients with metastatic breast cancer. However, in this randomized, placebo-controlled phase trial of 537 patients with advanced HER2-negative breast cancer we found that the combination of s...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Breast Cancer
Glavni autori: Baselga, José, Zamagni, Claudio, Gómez, Patricia, Bermejo, Begoña, Nagai, Shigenori E., Melichar, Bohuslav, Chan, Arlene, Mángel, Lászlo, Bergh, Jonas, Costa, Frederico, Gómez, Henry L., Gradishar, William J., Hudis, Clifford A., Rapoport, Bernardo L., Roché, Henri, Patricia, Maeda, Huang, Liping, Meinhardt, Gerold, Zhang, Joshua, Schwartzberg, Lee S.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5699974/
https://ncbi.nlm.nih.gov/pubmed/28830796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2017.05.006
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items